Pharmacological targeting of STK19 inhibits oncogenic NRAS-driven melanomagenesis
Activating mutations in NRAS account for 20%–30% of melanoma, but despite decades of research and in contrast to BRAF, no effective anti-NRAS therapies have been forthcoming. Here, we identify a previously uncharacterized serine/threonine kinase STK19 as a novel NRAS activator. STK19 phosphorylates...
| Main Authors: | , , , |
|---|---|
| Format: | Journal article |
| Published: |
Cell Press
2019
|